The chief medical officer at Edgewise Therapeutics gave an overview of the mechanism of EDG-5506, an agent in development for Becker muscular dystrophy, and its early promising clinical results to date. [WATCH TIME: 6 minutes]
Joanne Donovan, MD, PhD
Advertisement
Articles by Joanne Donovan, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
MDS Congress 2025: Top Expert Interviews and Key Takeaways
3
Earlier Initiation of Pimavanserin Leads to Better Improvement of Parkinson Disease Psychosis Symptoms
4
NeuroVoices: Gerald Maguire, MD, on Raising Awareness of the Neurobiology of Stuttering
5
